{"id":16319,"date":"2022-01-18T12:38:29","date_gmt":"2022-01-18T12:38:29","guid":{"rendered":"https:\/\/clinlabint.com\/?p=16319"},"modified":"2022-01-18T12:38:29","modified_gmt":"2022-01-18T12:38:29","slug":"molgen-opens-new-offices-in-uk-us","status":"publish","type":"post","link":"https:\/\/clinlabint.com\/molgen-opens-new-offices-in-uk-us\/","title":{"rendered":"MolGen opens new offices in UK, US"},"content":{"rendered":"
\n

\r\n\"Bio-Rad<\/a>\r\n<\/p>\n<\/div><\/section><\/div>

<\/p>\n<\/div><\/section>
\n

MolGen opens new offices in UK, US<\/h1>\/ in E-News<\/a> <\/span><\/span><\/header>\n<\/div><\/section>
\n

MolGen B.V., a provider of DNA \/ RNA extraction technology, has opened an office in London, UK. The new location will serve as a pivotal branch to provide laboratories in the UK with access to the company\u2019s extraction DNA \/ RNA portfolio across diagnostics, pharma and the biotech industry. The opening of the London office follows MolGen\u2019s opening of its US office in San Diego.<\/h3>\n

<\/p>\n

\u201cWe have been fortunate to experience such rapid growth as a company. Our ability to scale quickly has been a great asset as we continue to strive to meet the growing demand for our innovations. We see this new office as a way to further advance the testing and diagnostics industry and provide solutions as to how the world responds to disease and other life science conditions,\u201d said Niels Kruize, MolGen CCO.<\/p>\n

MolGen UK will serve as the launch point for MolGen\u2019s innovative product MegaPrep \u2013 a bi-weekly, non-invasive monitoring PCR test that gives users the ability to analyse up to a million samples a day. Using devices that can be customised to each lab, MegaPrep brings precision, speed and quality to the diagnostics workflow, resulting in accurate analysis at scale. As a pay-by-sample testing method it will help more parts of society, such as schools and business to remain open and combat disease, says the company.<\/p>\n<\/div><\/section>
\n

\"\"<\/div><\/div><\/div>
\n